Enteral Collagen Peptide Protein Market by Form (Liquid & Powder), Age Group (Adults (above 18) & Pediatrics (below 18), and End User (Hospital & Clinics, Nursing Home, and Homecare): Global Opportunity Analysis and Industry Forecast, 2021–2030

1.1.Report description

1.2.Key benefits for stakeholders

1.3.Key market segments

1.4.Research methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study

2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Market share analysis, 2020

3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in prevalence of chronic disorders

3.5.1.2.Surge in geriatric population

3.5.1.3.Rise in number of malnutrition cases

3.5.2.Restraint

3.5.2.1.Poor demand in underdeveloped countries

3.5.3.Opportunity

3.5.3.1.High growth potential in emerging markets

3.5.4.Impact analysis

3.6.COVID-19 impact analysis on enteral collagen peptide protein market

CHAPTER 4:ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM

4.1.Overview

4.1.1.Market size and forecast

4.2.Powder

4.2.1.Key market trends, growth factors, and opportunities

4.2.2.Market size and forecast, by region

4.2.3.Market analysis, by country

4.3.Liquid

4.3.1.Key market trends, growth factors, and opportunities

4.3.2.Market size and forecast, by region

4.3.3.Market analysis, by country

CHAPTER 5:ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP

5.1.Overview

5.1.1.Market size and forecast

5.2.Adults (above18)

5.2.1.Market size and forecast

5.2.2.Market analysis, by country

5.3.Pediatric (below 18 years)

5.3.1.Market size and forecast

5.3.2.Market analysis, by country

CHAPTER 6:ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospitals & clinics

6.2.1.Market size and forecast

6.2.2.Market analysis, by country

6.3.Homecare

6.3.1.Market size and forecast

6.3.2.Market analysis, by country

6.4.Nursing home

6.4.1.Market size and forecast

6.4.2.Market analysis, by country

CHAPTER 7:ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends and opportunities

7.2.2.Market size and forecast, by country

7.2.3.Market size and forecast, by form

7.2.4.Market size and forecast, by age group

7.2.5.Market size and forecast, by end user

7.2.6.U.S.

7.2.6.1.U.S. market size and forecast, by form

7.2.6.2.U.S. market size and forecast, by age group

7.2.6.3.U.S. market size and forecast, by end user

7.2.7.Canada

7.2.7.1.Canada market size and forecast, by Form

7.2.7.2.Canada market size and forecast, by age group

7.2.7.3.Canada market size and forecast, by end user

7.2.8.Mexico

7.2.8.1.Mexico market size and forecast, by form

7.2.8.2.Mexico market size and forecast, by age group

7.2.8.3.Mexico market size and forecast, by end user

7.3.Europe

7.3.1.Key market trends and opportunities

7.3.2.Market size and forecast, by country

7.3.3.Market size and forecast, by form

7.3.4.Market size and forecast, by age group

7.3.5.Market size and forecast, by end user

7.3.6.Germany

7.3.6.1.Germany market size and forecast, by form

7.3.6.2.Germany market size and forecast, by age group

7.3.6.3.Germany market size and forecast, by end user

7.3.7.France

7.3.7.1.France market size and forecast, by form

7.3.7.2.France market size and forecast, by age group

7.3.7.3.France market size and forecast, by end user

7.3.8.UK

7.3.8.1.UK market size and forecast, by form

7.3.8.2.UK market size and forecast, by age group

7.3.8.3.UK market size and forecast, by end user

7.3.9.Italy

7.3.9.1.Italy market size and forecast, by form

7.3.9.2.Italy market size and forecast, by age group

7.3.9.3.Italy market size and forecast, by end user

7.3.10.Spain

7.3.10.1.Spain market size and forecast, by form

7.3.10.2.Spain market size and forecast, by age group

7.3.10.3.Spain market size and forecast, by end user

7.3.11.Rest of Europe

7.3.11.1.Rest of Europe market size and forecast, by form

7.3.11.2.Rest of Europe market size and forecast, by age group

7.3.11.3.Rest of Europe market size and forecast, by end user

7.4.Asia-Pacific

7.4.1.Key market trends and opportunities

7.4.2.Market size and forecast, by country

7.4.3.Market size and forecast, by form

7.4.4.Market size and forecast, by age group

7.4.5.Market size and forecast, by end user

7.4.6.Japan

7.4.6.1.Japan market size and forecast, by form

7.4.6.2.Japan market size and forecast, by age group

7.4.6.3.Japan market size and forecast, by end user

7.4.7.China

7.4.7.1.China market size and forecast, by form

7.4.7.2.China market size and forecast, by age group

7.4.7.3.China market size and forecast, by end user

7.4.8.Australia

7.4.8.1.Australia market size and forecast, by form

7.4.8.2.Australia market size and forecast, by age group

7.4.8.3.Australia market size and forecast, by end user

7.4.9.India

7.4.9.1.India market size and forecast, by form

7.4.9.2.India market size and forecast, by age group

7.4.9.3.India market size and forecast, by end user

7.4.10.South Korea

7.4.10.1.South Korea market size and forecast, by form

7.4.10.2.South Korea market size and forecast, by age group

7.4.10.3.South Korea market size and forecast, by end user

7.4.11.Rest of Asia-Pacific

7.4.11.1.Rest of Asia-Pacific market size and forecast, by form

7.4.11.2.Rest of Asia-Pacific market size and forecast, by age group

7.4.11.3.Rest of Asia-Pacific market size and forecast, by end user

7.5.LAMEA

7.5.1.Key market trends and opportunities

7.5.2.Market size and forecast, by country

7.5.3.Market size and forecast, by form

7.5.4.Market size and forecast, by age group

7.5.5.Market size and forecast, by end user

7.5.6.Brazil

7.5.6.1.Brazil market size and forecast, by form

7.5.6.2.Brazil market size and forecast, by age group

7.5.6.3.Brazil market size and forecast, by end user

7.5.7.Saudi Arabia

7.5.7.1.Saudi Arabia market size and forecast, by form

7.5.7.2.Saudi Arabia market size and forecast, by age group

7.5.7.3.Saudi Arabia market size and forecast, by end user

7.5.8.South Africa

7.5.8.1.South Africa market size and forecast, by form

7.5.8.2.South Africa market size and forecast, by age group

7.5.8.3.South Africa market size and forecast, by end user

7.5.9.Rest of LAMEA

7.5.9.1.Rest of LAMEA market size and forecast, by form

7.5.9.2.Rest of LAMEA market size and forecast, by age group

7.5.9.3.Rest of LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

8.1.ABBOTT LABORATORIES

8.1.1.Company overview

8.1.2.Company snapshot

8.1.3.Operating business segments

8.1.4.Product portfolio

8.1.5.Business performance

8.2.DANONE S.A. (NUTRICIA)

8.2.1.Company overview

8.2.2.Company snapshot

8.2.3.Operating business segments

8.2.4.Product portfolio

8.2.5.Business performance

8.3.DERMARITE INDUSTRIES LLC

8.3.1.Company overview

8.3.2.Company snapshot

8.3.3.Operating business segments

8.3.4.Product portfolio

8.4.FRESENIUS KABI AG

8.4.1.Company overview

8.4.2.Company snapshot

8.4.3.Operating business segments

8.4.4.Product portfolio

8.4.5.Business performance

8.5.GLOBAL HEALTH PRODUCTS, INC.

8.5.1.Company overview

8.5.2.Company snapshot

8.5.3.Operating business segments

8.5.4.Product portfolio

8.6.MEDLINE INDUSTRIES, INC.

8.6.1.Company overview

8.6.2.Company snapshot

8.6.3.Operating business segments

8.6.4.Product portfolio

8.7.MEDTRITION INC.

8.7.1.Company overview

8.7.2.Company snapshot

8.7.3.Operating business segments

8.7.4.Product portfolio

8.8.OP2 LABS LLC

8.8.1.Company overview

8.8.2.Company snapshot

8.8.3.Operating business segments

8.8.4.Product portfolio

8.9.GELITA AG

8.9.1.Company overview

8.9.2.Company snapshot

8.9.3.Operating business segments

8.9.4.Product portfolio

8.9.5.Business performance

8.10.WEISHARDT HOLDING SA

8.10.1.Company overview

8.10.2.Company snapshot

8.10.3.Operating business segments

8.10.4.Product portfolio

TABLE 01.ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020–2030 ($THOUSAND)

TABLE 02.POWDER ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY REGION, 2020–2030 ($THOUSAND)

TABLE 03.LIQUID ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY REGION, 2020–2030 ($THOUSAND)

TABLE 04.GLOBAL ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 05.ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET FOR ADULTS (ABOVE18), BY REGION, 2020-2030 ($THOUSAND)

TABLE 06.ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET FOR PEDIATRIC (BELOW 18 YEARS), BY REGION, 2020–2030 ($THOUSAND)

TABLE 07.ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 08.ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET FOR HOSPITAL & CLINICS, BY REGION, 2020–2030 ($THOUSAND)

TABLE 09.ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET FOR HOMECARE, BY REGION, 2020–2030 ($THOUSAND)

TABLE 10.ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET FOR NURSING HOMES, BY REGION, 2020–2030 ($THOUSAND)

TABLE 11.ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY REGION, 2020–2030 ($THOUSAND)

TABLE 12.NORTH AMERICA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY COUNTRY, 2020–2030 ($THOUSAND)

TABLE 13.NORTH AMERICA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020–2030 ($THOUSAND)

TABLE 14.NORTH AMERICA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 15.NORTH AMERICA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 16.U.S. ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020–2030 ($THOUSAND)

TABLE 17.U.S. ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 18.U.S. ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 19.CANADA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020–2030 ($THOUSAND)

TABLE 20.CANADA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 21.CANADA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 22.MEXICO ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020–2030 ($MILLION)

TABLE 23.MEXICO ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 24.MEXICO ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 25.EUROPE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY COUNTRY, 2020–2030 ($THOUSAND)

TABLE 26.EUROPE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020–2030 ($THOUSAND)

TABLE 27.EUROPE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 28.EUROPE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 29.GERMANY ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020–2030 ($MILLION)

TABLE 30.GERMANY ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 31.GERMANY ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 32.FRANCE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020–2030 ($THOUSAND)

TABLE 33.FRANCE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 34.FRANCE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 35.UK ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020–2030 ($THOUSAND)

TABLE 36.UK ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 37.UK ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 38.ITALY ENTERAL COLLAGEN PEPTIDEP ROTEIN MARKET, BY FORM, 2020–2030 ($THOUSAND)

TABLE 39.ITALY ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 40.ITALY ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 41.SPAIN ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020–2030 ($THOUSAND)

TABLE 42.SPAIN ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 43.SPAIN ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 44.REST OF EUROPE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020–2030 ($THOUSAND)

TABLE 45.REST OF EUROPE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 46.REST OF EUROPE ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 47.ASIA-PACIFIC ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY COUNTRY, 2020–2030 ($THOUSAND)

TABLE 48.ASIA-PACIFIC ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020–2030 ($THOUSAND)

TABLE 49.ASIA-PACIFIC ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2039 ($THOUSAND)

TABLE 50.ASIA-PACIFIC ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 51.JAPAN ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020–2030 ($THOUSAND)

TABLE 52.JAPAN ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 53.JAPAN ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 54.CHINA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020–2030 ($THOUSAND)

TABLE 55.CHINA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 56.CHINA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 57.AUSTRALIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020–2030 ($THOUSAND)

TABLE 58.AUSTRALIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 59.AUSTRALIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 60.INDIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020–2030 ($THOUSAND)

TABLE 61.INDIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 62.INDIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 63.SOUTH KOREA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020–2030 ($THOUSAND)

TABLE 64.SOUTH KOREA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 65.SOUTH KOREA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 66.REST OF ASIA-PACIFIC ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020–2030 ($THOUSAND)

TABLE 67.REST OF ASIA-PACIFIC ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 68.REST OF ASIA-PACIFIC ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 69.LAMEA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY COUNTRY, 2020–2030 ($THOUSAND)

TABLE 70.LAMEA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020–2030 ($THOUSAND)

TABLE 71.LAMEA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 72.LAMEA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 73.BRAZIL ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020–2030 ($THOUSAND)

TABLE 74.BRAZIL ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 75.BRAZIL ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 76.SAUDI ARABIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020–2030 ($THOUSAND)

TABLE 77.SAUDI ARABIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 78.SAUDI ARABIA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 79.SOUTH AFRICA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET,BY FORM, 2020–2030 ($THOUSAND)

TABLE 80.SOUTH AFRICA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 81.SOUTH AFRICA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 82.REST OF LAMEA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY FORM, 2020–2030 ($THOUSAND)

TABLE 83.REST OF LAMEA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY AGE GROUP, 2020–2030 ($THOUSAND)

TABLE 84.REST OF LAMEA ENTERAL COLLAGEN PEPTIDE PROTEIN MARKET, BY END USER, 2020–2030 ($THOUSAND)

TABLE 85.ABBOTT: COMPANY SNAPSHOT

TABLE 86.ABBOTT: OPERATING SEGMENTS

TABLE 87.ABBOTT: PRODUCT PORTFOLIO

TABLE 88.DANONE: COMPANY SNAPSHOT

TABLE 89.DANONE: OPERATING SEGMENTS

TABLE 90.DANONE: PRODUCT PORTFOLIO

TABLE 91.DERMARITE: COMPANY SNAPSHOT

TABLE 92.DERMARITE: OERATING SEGMENT

TABLE 93.DERMARITE: PRODUCT PORTFOLIO

TABLE 94.FRESENIUS KABI AG: COMPANY SNAPSHOT

TABLE 95.FRESENIUS KABI AG: OPERATING SEGMENTS

TABLE 96.FRESENIUS KABI AG: PRODUCT PORTFOLIO

TABLE 97.GLOBAL HEALTH: COMPANY SNAPSHOT

TABLE 98.GLOBAL HEALTH: OPERATING SEGMENTS

TABLE 99.GLOBAL HEALTH: PRODUCT PORTFOLIO

TABLE 100.MEDLINE: COMPANY SNAPSHOT

TABLE 101.MEDLINE: OPERATING SEGMENTS

TABLE 102.MEDLINE: PRODUCT PORTFOLIO

TABLE 103.MEDTRITION: COMPANY SNAPSHOT

TABLE 104.MEDTRITION: OPERATING SEGMENTS

TABLE 105.MEDTRITION: PRODUCT PORTFOLIO

TABLE 106.OP2 LABS: COMPANY SNAPSHOT

TABLE 107.OP2 LABS: OERATING SEGMENT

TABLE 108.OP2 LABS: PRODUCT PORTFOLIO

TABLE 109.GELITA: COMPANY SNAPSHOT

TABLE 110.GELITA: OPERATING SEGMENTS

TABLE 111.GELITA: PRODUCT PORTFOLIO

TABLE 112.WEISHARDT: COMPANY SNAPSHOT

TABLE 113.WEISHARDT: OERATING SEGMENT

TABLE 114.WEISHARDT: PRODUCT PORTFOLIO